Journal ArticleDOI
Risks and benefits of calcium antagonists.
Reads0
Chats0
About:
This article is published in The Lancet.The article was published on 1995-10-07. It has received 12 citations till now.read more
Citations
More filters
Journal ArticleDOI
Conflict of Interest in the Debate over Calcium-Channel Antagonists
TL;DR: The recent debate over the safety of calcium-channel antagonists provided an opportunity to examine the effect of financial conflicts of interest in doctors' financial relationships with the pharmaceutical industry.
Journal ArticleDOI
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): Randomised controlled trial
Philip A. Poole-Wilson,Jacobus Lubsen,Bridget-Anne Kirwan,Fred J van Dalen,Gilbert Wagener,Nicolas Danchin,Hanjörg Just,Keith A.A. Fox,Stuart J. Pocock,Tim Clayton,Michael Motro,John D. Parker,Martial G. Bourassa,Anthony M. Dart,Per Hildebrandt,Åke Hjalmarson,Johannes A. Kragten,G Peter Molhoek,J.E. Otterstad,Ricardo Seabra-Gomes,Jordi Soler-Soler,Simon Weber +21 more
TL;DR: Addition of nifedipine GITS to conventional treatment of angina pectoris has no effect on major cardiovascular event-free survival and is safe and reduces the need for coronary angiography and interventions.
Journal ArticleDOI
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial
TL;DR: The salutary effects of the addition of nifedipine GITS to the basic regimen of patients with concurrent stable symptomatic coronary artery disease and hypertension emphasize the need for blood pressure control.
Journal ArticleDOI
A Comparative Review of the Adverse Effects of Calcium Antagonists
Hamish Dougall,James S. McLay +1 more
TL;DR: Of greater concern affecting the wide and common first-line use of calcium antagonists is the as-yet unresolved issue of a reportedly greater risk of myocardial infarction and death following the use of short-acting nifedipine in patients with a history of hypertension, myocardIAL infarctions or angina.
References
More filters
Journal ArticleDOI
Blood pressure, stroke, and coronary heart disease: Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context
Rory Collins,Richard Peto,Stephen MacMahon,Patricia R. Hebert,N H Fiebach,Kimberley Eberlein,Jon Godwin,Nawab Qizilbash,James O. Taylor,Charles H. Hennekens +9 more
TL;DR: A sufficiently high risk of stroke (perhaps because of age, blood pressure, or, in particular, history of cerebrovascular disease) may be the clearest indication for antihypertensive treatment.
Journal ArticleDOI
Nifedipine Dose-Related Increase in Mortality in Patients With Coronary Heart Disease
TL;DR: In patients with coronary disease, the use of short-acting nifedipine in moderate to high doses causes an increase in total mortality, and other calcium antagonists may have similar adverse effects, in particular those of the dihydropyridine type.
Journal ArticleDOI
The Risk of Myocardial Infarction Associated With Antihypertensive Drug Therapies
Bruce M. Psaty,Susan R. Heckbert,Thomas D. Koepsell,David S. Siscovick,Trivellore E. Raghunathan,Noel S. Weiss,Frits R. Rosendaal,Rozenn N. Lemaitre,Nicholas L. Smith,Patricia W. Wahl,Edward H. Wagner,Curt D. Furberg +11 more
TL;DR: The findings of this study support the current guidelines from the Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure that recommend diuretics and beta-blockers as first-line agents unless contraindicated, unacceptable, or not tolerated.
Journal ArticleDOI
Retardation of angiographic progression of coronary artery disease by nifedipine
P. R. Lichtlen,Wolfgang Rafflenbeul,Hartmut Hecker,Stefan Jost,Paul G. Hugenholtz,Jaap W. Deckers +5 more
TL;DR: In patients with mild CAD nifedipine substantially suppresses disease progression as shown by the appearance of new lesions detectable by quantitative coronary arteriography.
Book
Textbook of hypertension
TL;DR: 1. Epidemiology 2. Circulation in Hypertension 3. Pathogenesis 4. Target Organ Damage 5. Special Groups 6. Secondaryhypertension 7. Clinical Assessment 8. Treatment 9. The Hypertensive Patient in Society